Cevidra brings in biotech expert profile to drive the advent of next-generation medicines to the French market

Cevidra brings in biotech expert profile to drive the advent of next-generation medicines to the French market

We’re pleased to announce Loïc FIEVET, PharmD, PhD, will serve as a new Deputy Qualified Person of Cevidra company through its next chapter, as it aims to bring new #EarlyAccess medicines to French patients. 

After a first milestone in clinical trial bioproduction sites as QC manager, notably at EFS in collaboration with the CHU de Toulouse, he then advised multiple biotechnology companies as scientific expert of advanced therapy medicinal products (ATMP).

His arrival and network will open new perspectives in our #biotechnology and #ATMP portfolio. 

Welcome on Board!

 

More To Explore

Actualités

Cevidra joined the MabDesign network

MabDesign is a French association of the industrial sector of biomedicines. Created in 2014 in response to the call for projects “Filière Industriel Stratégique d’Avenir”,

Actualités

Back-to-Back Congress in London

Back to London in March 2022, Cevidra team will attend to the 8th RWE, Market Access, Pricing & Reimbursement Congress co-located with the Expanded Access